APOBEC3G/3A expression in human immunodeficiency virus type 1-infected individuals following initiation of antiretroviral therapy containing cenicriviroc or efavirenz

Daniela A. Covino, Cristina Purificato, Laura Catapano, Clementina M. Galluzzo, Maria Cristina Gauzzi, Stefano Vella, Eric Lefebvre, Star Seyedkazemi, Mauro Andreotti, Laura Fantuzzi

Research output: Contribution to journalArticle

Abstract

Apolipoprotein B mRNA editing enzyme catalytic polypeptide-like 3 (APOBEC3) family members are cytidine deaminases that play crucial roles in innate responses to retrovirus infection. The mechanisms by which some of these enzymes restrict human immunodeficiency virus type 1 (HIV-1) replication have been extensively investigated in vitro. However, little is known regarding how APOBEC3 proteins affect the pathogenesis of HIV-1 infection in vivo and how antiretroviral therapy influences their expression. In this work, a longitudinal analysis was performed to evaluate APOBEC3G/3A expression in peripheral blood mononuclear cells of antiretroviral-naive HIV-1-infected individuals treated with cenicriviroc (CVC) or efavirenz (EFV) at baseline and 4, 12, 24, and 48 weeks post-treatment follow-up. While APOBEC3G expression was unaffected by therapy, APOBEC3A levels increased in CVC but not EFV arm at week 48 of treatment. APOBEC3G expression correlated directly with CD4+ cell count and CD4+/CD8+ cell ratio, whereas APOBEC3A levels inversely correlated with plasma soluble CD14. These findings suggest that higher APOBEC3G/3A levels may be associated with protective effects against HIV-1 disease progression and chronic inflammation and warrant further studies.

Original languageEnglish
Article number1839
JournalFrontiers in Immunology
Volume9
Issue numberAUG
DOIs
Publication statusPublished - Aug 8 2018

Keywords

  • Antiretroviral therapy
  • APOBEC3A
  • APOBEC3G
  • Chronic inflammation
  • Disease progression
  • Cenicriviroc

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'APOBEC3G/3A expression in human immunodeficiency virus type 1-infected individuals following initiation of antiretroviral therapy containing cenicriviroc or efavirenz'. Together they form a unique fingerprint.

  • Cite this